ASAP Microlearning Volume 2
Newer Therapies, Treatment Transitions, and Diagnostic Pitfalls
Explore 18 new case-based questions on the decisions that come with newer therapies and updated guidance. Cases cover the pituitary incidentaloma workup, PTH replacement for hypoparathyroidism, insulin-delivery systems in the hospital, GLP-1 receptor agonists in MASH and thyroid cancer, menopausal hormone therapy, and long-term methimazole in Graves' disease.
Course overview
Volume 2 uses the same focused, case-based format as Volume 1 and covers a new set of clinical challenges. Its cases center on three practical questions:
When is a newer therapy the right choice? For example, PTH replacement for hypoparathyroidism or a GLP-1 receptor agonist for MASH.
How do you safely change or stop a treatment? For example, stopping denosumab, switching estrogen formulations, or moving from IV to subcutaneous insulin.
When could a test result be misleading? For example, alcohol-related cortisol elevation or testosterone measured by immunoassay.
Cases draw on recent guidance, including the 2026 ADA Standards of Care, the 2025 Endocrine Society guideline on primary aldosteronism, and the 2024 consensus report on hyperglycemic crises. Each question includes a clinical vignette, answer choices, a rationale for every option, and supporting references.
Topics you'll explore
- Adrenal and pituitary: Complete hormonal evaluation of a pituitary incidentaloma, the 2025 Endocrine Society recommendation to screen all adults with hypertension for primary aldosteronism, and distinguishing alcohol-related pseudo-Cushing states from Cushing syndrome.
- Bone and calcium: When to start PTH replacement therapy (palopegteriparatide) for hypoparathyroidism that is not controlled on conventional treatment, follow-on therapy after stopping denosumab, and choosing an anabolic agent for very high fracture risk after a recent myocardial infarction.
- Diabetes: Continuing an automated insulin delivery system during hospitalization under the 2026 ADA Standards of Care, weighing the benefits and risks of GLP-1 receptor agonists for biopsy-confirmed MASH, and resolving SGLT2 inhibitor-associated euglycemic DKA before switching to subcutaneous insulin.
- Lipids, obesity, and nutrition: Lipoprotein(a) as a risk-enhancing factor for starting a statin, and evidence on non-nutritive sweeteners in type 2 diabetes.
- Reproductive endocrinology: Confirming androgen excess in hirsutism with accurate testosterone assays, switching estrogen formulations to reduce VTE risk during feminizing hormone therapy, and starting menopausal hormone therapy within the window of greatest benefit.
- Thyroid: Deferring treatment of mild subclinical hypothyroidism in older adults, starting GLP-1 receptor agonist therapy in a patient with a history of differentiated thyroid cancer, and long-term low-dose methimazole for Graves' disease.
Course details
- Credit: Up to 3.0 AMA PRA Category 1 Credits™ and 3.0 ABIM MOC points for completing the entire volume
- Pricing: Nonmember: $60 | Informed Member: $48 | Engaged/Fellow Member: $36
- Access: On demand through AACE's Learning App for iOS and Android [confirm for Volume 2]
- Available: 10/23/2026 - 10/23/2029
- Intended audience: Clinical endocrinologists
10/23/2026
10/23/2029
After completing this course, learners should be better able to:
- Identify patients who are appropriate candidates for newer endocrine therapies, including PTH replacement, GLP-1 receptor agonists for MASH, and automated insulin delivery in the hospital.
- Plan safe treatment transitions, including follow-on therapy after denosumab, changes in estrogen route, and the switch from IV to subcutaneous insulin.
- Recognize conditions and testing methods that can produce misleading results and choose appropriate confirmatory testing.
- Apply updated guideline recommendations to screening and to long-term management decisions.
This program is intended for clinical endocrinologists.
Meet the ASAP Faculty
Learn about the endocrine experts who develop and lead ASAP Microlearning Volumes and Case Challenges.